Sha Zhao
Impact in
- Immunology top 2%
- Immune Cell Function and Interaction
- interferon and immune responses
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
- Oncology 53
- Cancer Immunotherapy and Biomarkers 27
- Lung Cancer Research Studies 22
- Peptidase Inhibition and Analysis 7
-
- MicroRNA in disease regulation 9
- Cancer-related molecular mechanisms research 8
Sha Zhao
94 papers receiving 3.4k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Immunology 1.2k
- Oncology 1.4k
- Cancer Research 745
- Pulmonary and Respiratory Medicine 785
- Molecular Biology 1.5k
Countries citing papers authored by Sha Zhao
This map shows the geographic impact of Sha Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sha Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sha Zhao more than expected).
Fields of papers citing papers by Sha Zhao
This network shows the impact of papers produced by Sha Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sha Zhao. The network helps show where Sha Zhao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sha Zhao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 12 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 11 | |
| 5 | 2021 | 10 | |
| 6 | 2021 | 8 | |
| 7 | Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy Hit paper breakdown → | 2021 | 203 |
| 8 | 2021 | 9 | |
| 9 | 2020 | 6 | |
| 10 | 2020 | 5 | |
| 11 | OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer | 2019 | 4 |
| 12 | High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer | 2019 | 1 |
| 13 | 2019 | 121 | |
| 14 | 2019 | 23 | |
| 15 | 2019 | 36 | |
| 16 | 2018 | 12 | |
| 17 | 2018 | 34 | |
| 18 | 2018 | 2 | |
| 19 | 2017 | 9 | |
| 20 | 2013 | 6 |
About Sha Zhao
Sha Zhao is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Nephrology, having authored 97 papers that have together received 3.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Research Studies (22 papers), MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (8 papers), Neuroendocrine Tumor Research Advances (8 papers), Peptidase Inhibition and Analysis (7 papers) and Immune Cell Function and Interaction (7 papers). The work is most often cited by research in Immunology (1.2k citations), Oncology (1.4k citations), Cancer Research (745 citations), Pulmonary and Respiratory Medicine (785 citations) and Molecular Biology (1.5k citations). Sha Zhao has collaborated with scholars based in China, United States and Poland. Frequent co-authors include Yayi He, Hai Long, Caicun Zhou, Minlin Jiang, Ming Zhao, Tao Jiang, Yijun Jia, Xuefei Li, Keyi Jia and Lei Wang. Their work appears in journals such as Translational Lung Cancer Research, OncoTargets and Therapy, Annals of Translational Medicine, Lung Cancer and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.